MedTrace Logo

Switch From Etravirine to Doravirine as a Part of Antiretroviral Combination

NCT06155019 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 109

Last updated 2025-01-10

No results posted yet for this study

Summary

The main objective of the SWEED study is to determine whether doravirine containing ART is able to maintain viral suppression at W48 in HIV-1 infected people living with HIV (PLWH) receiving etravirine containing ART:

* An ARV strategy containing doravirine as a replacement for etravirine can maintain virological suppression in participants with controlled viral replication under ARV treatment containing etravirine, with a virological success rate \>90%
* This strategy can maintain virological suppression even in the event of NNRTI resistance mutations acquired in the past
* This strategy is well tolerated
* The emergence of resistance to NNRTIs is uncommon in the event of virological failure under the ARV regimen containing doravirine

Conditions

  • HIV Infections

Sponsors & Collaborators

  • Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida

    lead OTHER

Principal Investigators

  • Romain PALICH, DR · Pitie-Salpetriere Hospital, Infectious Diseases department

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-08
Primary Completion
2024-05-31
Completion
2024-09-15

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06155019 on ClinicalTrials.gov